AI drug discovery company

Nutshell Therapeutics

Data as of Oct 17, 2026.

Company facts

Founded

2013

ReportedSource for founded (opens in new tab)
Headquarters

China (Shanghai)

ConfirmedSource for headquarters (opens in new tab)

Latest funding round

Round: Series C1
Date: Sep 15, 2026
Lead investor: Trustar Capital and Decheng Capital

ReportedSource for the latest round (opens in new tab)

Drugs on the board

NTS231 (NRF2 degrader)

IND in effect (FDA) per company

Cancers with aberrant NRF2 activation

Source for NTS231 (NRF2 degrader) (opens in new tab)

Recent news

Sep 25, 2026

FDA clears the IND for NTS231, an NRF2 molecular glue degrader

ConfirmedSource (opens in new tab)
Sep 15, 2026

Closes a Series C1 of tens of millions of US dollars

ReportedSource (opens in new tab)
Jul 2026

NTS071 (p53 Y220C reactivator) enters a US-China Phase 1b trial

ReportedSource (opens in new tab)

Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.

Spot an error? Tell me and I'll fix it.